Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) General Counsel Cindy Tahl sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $38.85, for a total value of $971,250.00. The transaction was disclosed in a filing with the SEC, which is […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) and GreenLight Biosciences (NASDAQ:GRNA – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Earnings & Valuation This table compares Fate Therapeutics and GreenLight […]
StockNews.com upgraded shares of Fate Therapeutics (NASDAQ:FATE – Get Rating) to a sell rating in a research note released on Thursday morning. Several other brokerages have also weighed in on FATE. HC Wainwright decreased their price objective on shares of Fate Therapeutics from $122.00 to $115.00 and set a buy rating for the company in […]
/PRNewswire/ ARCH Venture Partners, one of the world s leading early-stage technology venture firms, today announced new Venture Partners, including John.
Dhvanit Shah Launches Garuda Therapeutics With $72 Million Series A Financing indianewengland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indianewengland.com Daily Mail and Mail on Sunday newspapers.